{"id":4566,"date":"2022-06-10T02:30:00","date_gmt":"2022-06-10T02:30:00","guid":{"rendered":"https:\/\/preprod.treefrog.fr\/?p=4566"},"modified":"2022-06-10T14:48:02","modified_gmt":"2022-06-10T14:48:02","slug":"umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology","status":"publish","type":"post","link":"https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/","title":{"rendered":"Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Partnership combines Umoja\u2019s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics\u2019 biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"umoja\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"logo\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

SEATTLE and PESSAC, France \/ June 10th, 2022<\/strong> \u2013 Umoja Biopharma, Inc.<\/a>, an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, and TreeFrog Therapeutics<\/a>, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), announced today that they have entered into a collaboration to evaluate Umoja\u2019s iPSC platform within TreeFrog\u2019s C-Stem\u2122 technology for scalable expansion and immune cell differentiation in bioreactors.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201cTogether, the successful pairing of Umoja\u2019s RACR\u2122 engineered iPS cells and TreeFrog\u2019s C-Stem\u2122 technology could overcome several challenges facing ex vivo<\/em> allogeneic therapies,\u201d said Ryan Larson, Ph.D., Vice President and Head of Translational Science at Umoja. \u201cTwo major industry-wide challenges include the ability to scale iPSC-based culture while maintaining cell health, quality, and efficient immune cell differentiation. TreeFrog\u2019s biomimetic C-Stem\u2122 technology is the perfect complementary development platform for our RACR\u2122 technology, a pairing which could result in controlled, efficient iPSC expansion and differentiation into immune cells, with improved yields and quality. In addition to enhancing the differentiation and yield of immune cells within the manufacturing process, our RACR\u2122 system should bring therapeutic benefit to patients, allowing for safe in vivo<\/em> engraftment and persistence of tumor-killing cells without requirements for toxic lymphodepleting chemotherapy.\u201d<\/p>

Umoja is developing an engineered iPSC platform that addresses many challenges associated with ex vivo<\/em> cell therapy manufacturing, including limited scalability and manufacturing complexity. Umoja\u2019s iPSCs are engineered with a synthetic rapamycin-activated cytokine receptor (RACR\u2122) to drive differentiation to, and expansion of innate cytotoxic lymphoid cells, including but not limited to natural killer (NK) cells in the absence of exogenous cytokines and feeder cells. TreeFrog\u2019s proprietary C-Stem\u2122 technology relies on the high-throughput encapsulation (>1,000 capsules\/second) of hiPSCs within biomimetic alginate shells, which promote in vivo<\/em>-like exponential growth and protect cells from external stress. In 2021, C-Stem\u2122 was demonstrated to allow for unprecedented iPSC expansion in 10L bioreactors, while preserving stem cell quality. Also enabling direct in-capsule iPSC differentiation, C-Stem\u2122 constitutes a scalable, end-to-end, and GMP-compatible manufacturing platform for iPSC-derived cell therapies.<\/p>

Fr\u00e9d\u00e9ric Desdouits, Ph.D., Chief Executive Officer at TreeFrog added \u201cOur primary goal is to bring the benefits of the C-Stem\u2122 technology to patients as fast as possible, either through in-house programs or strategic alliances with cell therapy leaders. Partnering with Umoja is an important step forward in immuno-oncology. Besides scale-up and cell quality, the in vivo<\/em> persistence of allogeneic therapies remains a critical challenge in the industry. We believe Umoja\u2019s platform will allow for safer and more efficient allogeneic cell therapies in immuno-oncology. \u00a0We look forward to rapidly advancing this joint approach to clinic and contributing to the future of off-the shelf cancer treatments.\u201d<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
About Umoja Biopharma<\/strong><\/h5>

Umoja Biopharma, Inc. is an early clinical-stage company advancing an entirely new approach to immunotherapy. Umoja Biopharma, Inc. is a transformative multi-platform immuno-oncology company founded with the goal of creating curative treatments for solid and hematological malignancies by reprogramming immune cells in vivo<\/em> to target and fight cancer. Founded based on pioneering work performed at Seattle Children\u2019s Research Institute and Purdue University, Umoja\u2019s novel approach is powered by integrated cellular immunotherapy technologies including the VivoVec\u2122 in vivo<\/em> delivery platform, the RACR\u2122\/CAR in vivo<\/em> cell expansion\/control platform, and the TumorTag\u2122 targeting platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely, and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives.
To learn more, visit\u00a0http:\/\/umoja-biopharma.com\/<\/a>.<\/p>

About TreeFrog Therapeutics<\/strong><\/h5>

TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem\u2122 technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 80 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline in regenerative medicine and immuno-oncology. The company is currently opening technological hubs in Boston, USA, and Kobe, Japan, to drive the adoption of C-Stem\u2122 and build strategic alliances with leading academic, biotech and industry players in the field of cell therapy.<\/p>

To learn more, visit\u00a0https:\/\/preprod.treefrog.fr\/<\/a><\/p>

Umoja Biopharma Media Contact:<\/strong><\/p>

Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com<\/a><\/p>


TreeFrog Therapeutics Media Contact:<\/strong><\/h5>

Pierre-Emmanuel Gaultier
+ 33 6 45 77 42 58
pierre@treefrog.fr<\/a><\/p>

\u00a0<\/span><\/p>

Download picture<\/a>
Caption : Mass-production of human induced pluripotent stem cells in a 10L bioreactor using TreeFrog Therapeutics’ C-Stem<\/span>\u2122 technology. Photo credits : TreeFrog Therapeutics<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Partnership combines Umoja\u2019s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics\u2019 biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors. SEATTLE and PESSAC, France \/ June 10th, 2022 \u2013 Umoja Biopharma, Inc., an immuno-oncology company pioneering…<\/p>\n","protected":false},"author":1,"featured_media":4568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[12,13],"tags":[],"aioseo_notices":[],"yoast_head":"\nUmoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology - TreeFrog Therapeutics I iPS-derived cell therapies<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology - TreeFrog Therapeutics I iPS-derived cell therapies\" \/>\n<meta property=\"og:description\" content=\"Partnership combines Umoja\u2019s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics\u2019 biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors. SEATTLE and PESSAC, France \/ June 10th, 2022 \u2013 Umoja Biopharma, Inc., an immuno-oncology company pioneering...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"TreeFrog Therapeutics I iPS-derived cell therapies\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-10T02:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-10T14:48:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/preprod.treefrog.fr\/wp-content\/uploads\/2022\/06\/270x-human-iPS-cell-amplification-in-10L-bioreactor-TreeFrog-C-Stem.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1152\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Piergueritona\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/\",\"url\":\"https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/\",\"name\":\"Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology - TreeFrog Therapeutics I iPS-derived cell therapies\",\"isPartOf\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/#website\"},\"datePublished\":\"2022-06-10T02:30:00+00:00\",\"dateModified\":\"2022-06-10T14:48:02+00:00\",\"author\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220\"},\"breadcrumb\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/preprod.treefrog.fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/preprod.treefrog.fr\/#website\",\"url\":\"https:\/\/preprod.treefrog.fr\/\",\"name\":\"TreeFrog Therapeutics I iPS-derived cell therapies\",\"description\":\"Cell Therapy for All\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/preprod.treefrog.fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220\",\"name\":\"Piergueritona\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g\",\"caption\":\"Piergueritona\"},\"sameAs\":[\"https:\/\/preprod.treefrog.fr\"],\"url\":\"https:\/\/preprod.treefrog.fr\/author\/piergueritona\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology - TreeFrog Therapeutics I iPS-derived cell therapies","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology - TreeFrog Therapeutics I iPS-derived cell therapies","og_description":"Partnership combines Umoja\u2019s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics\u2019 biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors. SEATTLE and PESSAC, France \/ June 10th, 2022 \u2013 Umoja Biopharma, Inc., an immuno-oncology company pioneering...","og_url":"https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/","og_site_name":"TreeFrog Therapeutics I iPS-derived cell therapies","article_published_time":"2022-06-10T02:30:00+00:00","article_modified_time":"2022-06-10T14:48:02+00:00","og_image":[{"width":2048,"height":1152,"url":"https:\/\/preprod.treefrog.fr\/wp-content\/uploads\/2022\/06\/270x-human-iPS-cell-amplification-in-10L-bioreactor-TreeFrog-C-Stem.jpg","type":"image\/jpeg"}],"author":"Piergueritona","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/","url":"https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/","name":"Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology - TreeFrog Therapeutics I iPS-derived cell therapies","isPartOf":{"@id":"https:\/\/preprod.treefrog.fr\/#website"},"datePublished":"2022-06-10T02:30:00+00:00","dateModified":"2022-06-10T14:48:02+00:00","author":{"@id":"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220"},"breadcrumb":{"@id":"https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/preprod.treefrog.fr\/umoja-biopharma-and-treefrog-therapeutics-announce-collaboration-to-address-current-challenges-facing-ex-vivo-allogeneic-therapies-in-immuno-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/preprod.treefrog.fr\/"},{"@type":"ListItem","position":2,"name":"Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology"}]},{"@type":"WebSite","@id":"https:\/\/preprod.treefrog.fr\/#website","url":"https:\/\/preprod.treefrog.fr\/","name":"TreeFrog Therapeutics I iPS-derived cell therapies","description":"Cell Therapy for All","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/preprod.treefrog.fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220","name":"Piergueritona","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g","caption":"Piergueritona"},"sameAs":["https:\/\/preprod.treefrog.fr"],"url":"https:\/\/preprod.treefrog.fr\/author\/piergueritona\/"}]}},"_links":{"self":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts\/4566"}],"collection":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/comments?post=4566"}],"version-history":[{"count":33,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts\/4566\/revisions"}],"predecessor-version":[{"id":4609,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts\/4566\/revisions\/4609"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/media\/4568"}],"wp:attachment":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/media?parent=4566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/categories?post=4566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/tags?post=4566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}